Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase Ib trial studies the safety and best dose of wild-type reovirus in combination with bortezomib and dexamethasone and to see how well they work in treating patients with multiple myeloma that has returned (relapsed) or does not respond to treatment (refractory). A virus, called wild-type reovirus, may be able to infect cancer cells and slow the cancer growth and kill cancer cells. Bortezomib and dexamethasone may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving wild-type reovirus together with bortezomib and dexamethasone may be a better treatment for multiple myeloma.
|Condition or Disease||Intervention/Treatment||Phase|
- To determine the maximum tolerated dose (MTD) with the maximum REOLYSIN (wild-type reovirus) dose limited to 4.5 x 10^10 tissue culture infection dose (TCID)50 and the safety profile of REOLYSIN in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). (Phase 1b) II. To further explore the safety and tolerability of the combination and to determine the overall response rate (ORR) (complete response [CR] + partial response [PR]) to REOLYSIN in combination with bortezomib and dexamethasone in patients with relapsed or refractory MM. (Phase 1b Dose Expansion)
To determine ORR in the Phase 1b part to the combination at escalating doses.
To determine the progression-free survival (PFS) of patients with relapsed or refractory MM treated with REOLYSIN in combination with bortezomib and dexamethasone.
To evaluate the effect of REOLYSIN in combination with bortezomib and dexamethasone treatments on overall survival (OS).
To conduct pharmacodynamic studies as described.
OUTLINE: This is a phase Ib, dose-escalation study of wild-type reovirus followed by a phase Ib expansion trial.
Patients receive dexamethasone orally (PO), intravenously (IV), or intramuscularly (IM) and bortezomib subcutaneously (SC) (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month and then every 3 months thereafter.
Arms and Interventions
|Experimental: Treatment (dexamethasone, bortezomib, wild-type reovirus)
Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Given SC or IV
Given PO, IV, or IM
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Wild-type Reovirus
Primary Outcome Measures
- Incidence of adverse events assessed by CTCAE version 4.03 [Up to 30 days post-treatment]
The safety of the bortezomib, dexamethasone, and wild-type reovirus combination will be assessed by the evaluation of the type, frequency, and severity of adverse events.
Secondary Outcome Measures
- ORR [Up to 3 years]
Will determine ORR (CR + PR) in the Phase 1b part to the combination at escalating doses.
Have relapsed or refractory MM after at least one line of therapy
Have a confirmed diagnosis of MM with measurable disease, as defined by the presence of monoclonal immunoglobulin protein in serum electrophoreses of at least 0.5 g/dL for immunoglobulin G (IgG) or 0.25 g/dL for IgA, or measurable light chain in serum (100 mg/L) or urinary excretion of at least 200 mg monoclonal light chain per 24 hours
Have NO continuing acute toxic effects (except alopecia) of any prior chemotherapy, radiotherapy or surgical procedures; all such effects must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) grade =< 1; surgery (except minor procedures such as biopsies, IV line placement, etc.) must have occurred at least 28 days prior to study enrollment
Have received NO anti-cancer therapy within 28 days prior to receiving study drug
Have received NO radiotherapy within 14 days prior to receiving study drug
Have an Eastern Cooperative Oncology Group (ECOG) Performance score =< 2
Have a life expectancy of at least 3 months
Absolute neutrophil count (ANC) >= 1 x 109 (International System [SI] units 109/L) (with or without filgrastim [G-CSF])
Platelets >= 50 x109 (SI units 109/L)
Serum creatinine =< 2 x upper limit of normal (ULN)
Bilirubin =< 1.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN if patients have liver involvement with MM)
Proteinuria < grade 2
Have a negative pregnancy test if a female with childbearing potential
Have signed an informed consent indicating that the patient is aware of the neoplastic nature of their disease and have been informed of the procedures of the protocol, the experimental nature of the therapy, possible alternative therapies, potential benefits, side effects, risks, and discomforts
Be willing and able to comply with scheduled visits, the treatment plan, and laboratory tests
Have a history of or current evidence of intracranial disease; patients with brain metastases must be excluded from this clinical trial
Be on immunosuppressive therapy or have human immunodeficiency virus (HIV) infection or active hepatitis B or C
Be a pregnant or breast-feeding woman; female patients of childbearing potential must agree to use effective contraception, must be surgically sterile, or must be postmenopausal; male patients must agree to use effective contraception or be surgically sterile; barrier methods are a recommended form of contraception
Have clinically significant cardiac disease (New York Heart Association, class III or
- including pre-existing arrhythmia, uncontrolled angina pectoris, myocardial infarction 1 year prior to study entry, or a known history of grade 2 or higher compromised left ventricular ejection fraction
Have dementia or altered mental status that would prohibit informed consent
Have any other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the principal investigator, would make the patient inappropriate for this study
Have a history of allergic (anaphylactic) sensitivity to bortezomib, boron or mannitol
Have grade 2 or greater neuropathy at the time of screening
Contacts and Locations
|1||USC / Norris Comprehensive Cancer Center||Los Angeles||California||United States||90033|
Sponsors and Collaborators
- University of Southern California
- National Cancer Institute (NCI)
- Oncolytics Biotech
- Principal Investigator: Kevin Kelly, MD, University of Southern California
Study Documents (Full-Text)None provided.
- REO 019